NCT07426484 2026-02-23
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
Dana-Farber Cancer Institute
Phase 4 Not yet recruiting
Dana-Farber Cancer Institute
University of Oklahoma
Charite University, Berlin, Germany
Zealand University Hospital
University Hospitals Cleveland Medical Center
Goldman, Butterwick, Fitzpatrick and Groff
University of Zurich